Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Instagram Outage Disrupts Thousands of U.S. Users 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
ZUG, Switzerland, April 05, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 2:20 p.m. EDT from The Westin New York Grand Central hotel in New York City. The webcast will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications +41 61 201 1350, [email protected] Agency contact: Matthew P. Duffy, Managing Director, LifeSci Advisors 212-915-0685, [email protected]
